.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CR05_PiperacillinAndBetaLactamaseInhi.PiperacillinAndBetaLactamaseInhi .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CR05_PiperacillinAndBetaLactamaseInhi.PiperacillinAndBetaLactamaseInhi| name: | PiperacillinAndBetaLactamaseInhibitor |
| ATC code: | J01CR05 | route: | intravenous |
| n-compartments | 2 |
Piperacillin is a broad-spectrum injectable penicillin-class antibiotic, usually co-administered with tazobactam, a beta-lactamase inhibitor. The combination is used for the treatment of moderate to severe bacterial infections including intra-abdominal, skin, gynecological, and nosocomial respiratory tract infections caused by susceptible organisms. This combination is approved and widely used today.
Pharmacokinetic parameters reported for piperacillin/tazobactam in healthy adult volunteers (mostly male and female, mean age ~29-35 years) after single intravenous dose.
Chen, R, et al., & Wang, LY (2016). Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. European journal of drug metabolism and pharmacokinetics 41(4) 363–372. DOI:10.1007/s13318-015-0276-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25894901
Alobaid, AS, et al., & Roberts, JA (2017). Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Antimicrobial agents and chemotherapy 61(3) –. DOI:10.1128/AAC.01276-16 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28052849
Cojutti, PG, et al., & Pea, F (2024). Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing . Antimicrobial agents and chemotherapy 68(4) e0140423–None. DOI:10.1128/aac.01404-23 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38411995